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Abstract
Background—The prevalence and characteristics of the continuum of diagnoses within fetal 
alcohol spectrum disorders (FASD) were researched in a fifth sample in a South African 
community.
Methods—An active case ascertainment approach was employed among all first grade learners in 
this community (n=862). Following individual examination by clinical geneticists/ 
dysmorphologists, cognitive/behavioral testing, and maternal interviews, final diagnoses were 
made in multidisciplinary case conferences.
Results—Physical measurements, cardinal facial features of FAS, and total dysmorphology 
scores clearly differentiated diagnostic categories in a consistent, linear fashion, from severe to 
mild. Neurodevelopmental delays and behavioral problems were significantly worse for each of 
the FASD diagnostic categories, although not as consistently linear across diagnostic groups. 
Alcohol use was documented by direct report from the mother in 71% to 100% of cases in specific 
diagnostic groups. Significant distal maternal risk factors in this population are: advanced maternal 
age at pregnancy; low height, weight, and body mass index (BMI); small head circumference; low 
education; low income; and rural residence. Even when controlling for socioeconomic status, 
prenatal drinking correlates significantly with total dysmorphology score, head circumference, and 
five cognitive and behavioral measures. In this community, FAS occurs in 59 – 79 per 1,000 
children, and total FASD in 170 – 233 per 1,000 children, or 17% to 23%.
Conclusions—Very high rates of FASD continue in this community where entrenched practices 
of regular binge drinking co-exist with challenging conditions for childbearing and child 
development in a significant portion of the population.
Keywords
fetal alcohol spectrum disorders (FASD); prenatal alcohol use; microcephaly; alcohol abuse; binge 
drinking; maternal risk for FASD; prevalence; children with FASD; South Africa
1. INTRODUCTION
1.1 Diagnosing a continuum
The diagnosis of a continuum of disabilities associated with prenatal alcohol exposure has 
evolved since fetal alcohol syndrome (FAS) was first defined by Jones and Smith (1973). 
Children with significant dysmorphia and cognitive/behavioral impairments were identified 
as FAS. Soon thereafter, less consistent, less severe patterns of dysmorphia and 
neurobehavioral impairment were recognized in animal and human studies and referred to as 
fetal alcohol effects (Aase, 1994; Aase et al., 1995; Clarren et al., 1978). Four specific 
diagnostic categories were later created by a committee of the Institute of Medicine (IOM): 
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FAS, partial FAS (PFAS), alcohol-related birth defects (ARBD), and alcohol-related 
neurodevelopmental disorder (ARND; Stratton et al., 1996). These four diagnoses form a 
continuum from the most dysmorphic to least dysmorphic and were later referred to as fetal 
alcohol spectrum disorders (FASD; Streissguth and O’Malley, 2000; Warren et al., 2004). 
FASD are rarely diagnosed or diagnosed properly even within advanced health care 
institutions which colors the understanding of the full continuum of FASD. For example, in 
one study in the United States (USA) 80% of children with FASD had not been diagnosed at 
all, and 7% were misdiagnosed (Chasnoff et al., 2015). Because of this, FASD epidemiology 
information gathered through registries or summarized from clinic data of diagnosed cases 
are inaccurate for understanding prevalence and characteristics of FASD in general 
populations (Fox et al., 2015). Epidemiologic studies of FASD are difficult to pursue and 
expensive (Stratton et al., 1996). Few studies have documented the prevalence and 
characteristics of the continuum of FASD in general populations, especially in the USA and 
Europe (May and Gossage, 2001; Sampson et al., 1997). But recent studies indicate that 
FASD prevalence is approximately 2 to 5% in general populations of the USA, Italy, Poland, 
and Croatia (May et al., 2009, 2011a, 2014a, 2015; Okulicz-Kozaryn, Borkowska, Brzozka, 
2015; Petković and Barišić, 2010, 2013).
1.2 FASD epidemiology studies in South Africa
Some communities in South Africa (ZA) have a higher prevalence of FASD than any other 
general populations studied to date. From an epidemiologic perspective, ZA has proven an 
excellent venue for implementing active case ascertainment methods for understanding 
general population patterns and the diagnosis, prevalence, characteristics, and etiology of 
FASD. Many characteristics of FASD have been described in four previous studies of the 
single municipality and surrounding rural areas in the Western Cape Province (WCP) 
studied here (May et al., 2000, 2007, 2013a; Viljoen et al., 2005). Other researchers have 
independently completed FASD studies in other ZA communities with similar patterns and 
rates (Olivier et al., 2013; Urban et al., 2008, 2015; Viljoen et al., 2003). From previous 
studies in ZA communities, research evolved from an exclusive focus on FAS to delineating 
and understanding all diagnoses of FASD. In recent publications from this community, FAS 
affected 59 – 91 per 1,000 children, and total FASD rates were 135 – 208 per 1,000 (13.5 to 
20.8%; May et al., 2013a). Norms and practices of regular, consistent, weekend binge 
drinking, low socioeconomic status (SES), insufficient nutrition, high fertility, and 
challenging conditions for prenatal and postnatal development combine to elevate prevalence 
and severity of FASD (May et al., 2005, 2008, 2013b, 2014b, 2016a; Viljoen et al., 2002).
1.3 The current study
As before, active case ascertainment methodology was employed by a multidisciplinary field 
research team with offices in the community and dysmorphologists from the USA. The 
approach and methods of general population research on FASD have been pioneered and 
fully developed in this locale (population = 50,000) characterized by small industries and 
multiple farms producing vegetables, poultry, grapes and other fruits, and wine.
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2. METHODS
2.1 Sampling and recruitment
Active, written consent for children to participate in the study was obtained from parents/
guardians of 862 (73.5%) first grade pupils enrolled in all 13 primary schools of the 
community; and assent forms were obtained from children seven years and older. As in 
Figure 1, a three-tier process of screening, data collection, and diagnosis was instituted. In 
Tier I all consented children were measured for height, weight, and head circumference. If a 
child was ≤ 25th centile on height, weight, and/or occipitofrontal (head) circumference 
(OFC), he/she was advanced to Tier II. In addition, 450 child enrollment numbers were 
picked randomly as potential controls (typically developing/not FASD comparison children) 
from all children on the school roles, and 353 had consent to participate. Each qualifying 
child (small and/or randomly-selected) was advanced to Tier II where he/she received a 
standardized, blinded physical examination by a dysmorphologist. Of those advanced to Tier 
III, the racial composition mirrored the community: 83% Coloured (mixed race), 11% 
Black, and 6% White.
2.2 IOM diagnostic categories
The IOM criteria for the specific diagnoses in the FASD continuum are presented in Figure 
2 and described in more detail elsewhere (Hoyme et al., 2005, 2015). Significant growth 
restriction and marked dysmorphia are present in children with FAS, and less growth 
restriction and dysmorphia in children with PFAS; however, at least two of three cardinal 
facial features and a constellation of other minor anomalies are present with both FAS and 
PFAS. The clinical traits of FAS and PFAS have been clearly linked with prenatal alcohol 
exposure in thousands of cases and multiple correlation studies (May et al., 2011b, 2013b, 
2016b); and these two diagnoses can be made by experienced physicians without direct 
documentation of alcohol exposure, after ruling out other malformation syndromes with 
similar phenotypes. In previous studies in WCP communities, it has rarely been necessary to 
diagnose a child with FAS or PFAS without strong evidence of prenatal alcohol use (May et 
al., 2008, 2013b). Women in this population are candid, the interviewing format and 
contexts are effective, and our staff interviewers are experienced and long-term residents of 
the region. Children with ARND do not have a characteristic pattern of facial characteristics; 
therefore, direct evidence of prenatal alcohol exposure and significant cognitive impairment 
are required.
2.3 Assessment of cognitive and behavioral traits
In Tier III, all randomly-selected control candidates and all children with features of a 
diagnosis within FASD were advanced to cognitive testing and teachers completed 
Achenbach Teacher Report Forms (TRF; Achenbach and Rescorla, 2001) to evaluate 
inattention and behavioral issues. Tests administered to all children in Tier III were: Test of 
Reception of Grammar (TROG; Bishop, 1989) for verbal abilities; Raven Coloured 
Progressive Matrices (Raven, 1981) for nonverbal, fluid intelligence; and the Digit Span 
subtest of the Wechsler Intelligence Scales for Children, Third Edition (WISC-III; Wechsler, 
1997) for working memory. Tests were administered by blinded psychometrists, mostly in 
Afrikaans, although 5% were in English, and 5% were in Xhosa for the Black African 
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children. Although centile scores were referenced from the standard charts of the Raven and 
the TROG, in addition, a normal curve was calculated for the cohort prior to the final case 
conference, so that the team had a true sense of the cohort’s abilities compared to the norms 
for each instrument used. This was undertaken for two reasons: 1) this population is 
significantly disadvantaged and 2) this population was not included in normative samples for 
any of the tests used. Any scores falling at the 7th percentile or below were 1.5 standard 
deviations below the mean and were considered impaired. The score reported for the Digit 
Span is scaled with a mean of 10 and standard deviation of +3. The two scores of the 
Achenbach (total problems and inattention) were scored as follows: total problem T score ≥ 
64 and an inattention T score of ≥ 22 were in the clinical range.
2.4 Maternal risk factor assessment: proximal and distal variables
Also, every Tier III child’s mother that consented (n=491; 87.5%) was interviewed in person 
(96% in Afrikaans) regarding maternal risk for FASD in the index pregnancy. The interviews 
used time-line follow back methods (Sobel et al., 1988, 2001) adapted to a specific medical 
history format. Similar questions have been used effectively and successfully in other ZA 
studies by our team and other experienced researchers (Jacobson et al., 2008; Viljoen et al., 
2002). Proximal variables assessed included alcohol use by quantity, frequency, and timing 
during pregnancy and when breastfeeding (May et al., 2016c). Distal variables of maternal 
risk were addressed, including: maternal height, weight, and OFC; childbearing history; and 
demographic variables. All questions were contextual to medical history and dietary intake 
(King, 1994). In previous ZA community studies, direct, substantially accurate maternal 
reports of prenatal alcohol use were obtained from most mothers, and in this sample 
consultation with knowledgeable collateral informants about the index pregnancy was 
necessary in only a few instances. Overall, 89.7%, 70.6%, 100%, and 41% of the mothers of 
FAS, PFAS, ARND, and controls, respectively, reported drinking alcohol during the index 
pregnancy. Death, moving from the study area, multiple missed appointments, and a few 
outright refusals accounted for no interviews with 70 mothers (12.5%).
2.5 Case conference for final diagnosis
Final diagnoses were made for each child in a multidisciplinary case conference where data 
and findings from each domain (growth, dysmorphology, cognitive/behavioral performance, 
and maternal risk) were reviewed and assessed by research team members who had 
performed the exams, testing, and maternal interviews. After review and discussion for each 
child, final diagnoses were made by the dysmorphologists.
2.6 Statistical analysis
Data were processed with Excel (Microsoft, 2010) and analyzed with SPSS 23 (IBM, 2014). 
Case control analysis compares results across FASD diagnostic groups and controls. 
Statistical significance was determined using chi-square and one-way analysis of variance 
(ANOVA) using Bonferroni-adjusted values for interpretation as indicated on each table 
(Tabachnick and Fidel, 2013). With statistically significant ANOVAs, post-hoc analyses 
were performed using Dunnett’s pairwise comparisons (α = .05). Table 5 employs partial 
correlation analysis of associations between prenatal drinking and select child outcomes, 
after adjusting for two SES measures. Even though optimizing SES conditions has not been 
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found to significantly affect functioning and development in many severely-affected children 
with FAS in adoption studies (Landgren et al., 2010), SES has been demonstrated to have a 
significant independent effect on physical growth and neurodevelopment in community 
studies in ZA (May et al., 2011, 2013c).
3. RESULTS
3.1 Child physical growth and physical development and dysmorphology
In Table 1, mean values are presented for demographic, growth, and the three cardinal facial 
variables for the FASD diagnostic continuum and controls. Children with FASD were 
properly classified by the revised IOM criteria and therefore were significantly different 
from controls on height, weight, BMI, OFC, and cardinal facial features of FAS (palpebral 
fissure length (PFL), smooth philtrum, and narrow vermilion). Age differed among groups in 
the sample; FASD children were slightly older because poor performance kept some from 
advancing to 2nd grade. Only the proportion of male and female subjects was similar across 
groups. Pairwise differences for weight, BMI, and OFC were significantly different for the 
majority of comparisons among groups. Most importantly, head circumference was the 
single trait that most distinguished each group from one another in Dunnett comparisons: 
76.8% of the children with FAS had a head circumference < 3rd centile (< 2 standard 
deviations below the mean), while 8.8% of those with PFAS, and 43.6% with ARND were < 
3rd centile. These head circumference data are best explained by the diagnostic criteria 
employed which require a small OFC for the assignment of a diagnosis of FAS, as opposed 
to its being optional in PFAS. In addition, in the current study any child with an OFC < 10th 
centile who lacked the requisite facial dysmorphology was deferred to rule out ARND.
Also in Table 1, total dysmorphology score means summarize the total of all FASD-relevant 
minor anomalies found in children of each group (see Hoyme et al., 2005). Scores were 
significantly different across groups: the FAS group was the highest (18.3), then PFAS 
(13.2), ARND (11.1), and controls (6.7). Variance within each group was relatively equal 
(SD=3.2–3.8). Mean dysmorphology scores form a linear continuum across FASD groups 
and controls (Figure 3). Head circumference is not as linear due to a small OFC being 
optional in PFAS. In the post-hoc analyses, each diagnostic group was significantly 
differentiated from the other by total dysmorphology.
3.2 Other minor anomalies
Table 2 details other minor anomalies by diagnostic group. Maxillary and mandibular arcs, 
inner canthal distance, and inter-pupillary distance, hypoplastic midface, epicanthal folds, 
ptosis, camptodactyly, flat nasal bridge, altered palmar creases, and prognathism are 
significantly different across groups. The PFAS group is sometimes an exception, indicating 
greater variability in this group.
3.3 Cognitive and behavioral traits
Cognitive testing and behavior checklist results (Table 3) indicate low average achievement 
levels for all community children and significant statistical differences between diagnostic 
groups with Bonferroni-adjusted values. Controls performed best on each measure. FASD 
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groups performed significantly worse on each cognitive measure: verbal and non-verbal 
ability and working memory. Children with FAS performed most poorly on cognitive 
measures, followed by those with ARND and then PFAS. Those with ARND had the most 
behavior problems, followed by PFAS and FAS and inattention was also worst for children 
with ARND, followed by FAS and PFAS. Post-hoc analysis indicated that all tests/checklists 
distinguished each FASD diagnostic groups from controls. Notably, PFAS and ARND 
groups were significantly different from one another on verbal IQ and the Digit Span, with 
PFAS performing better than ARND. Working memory (Digit Span) was the only measure 
where each group was significantly different from one another (Figure 4).
3.4 Proximal maternal risk– alcohol use in the index pregnancy
Among mothers of normal controls, 59% abstained and 41% drank during the index 
pregnancy. The children of the latter mothers were neither significantly dysmorphic nor 
neurobehaviorally impaired enough to qualify for a FASD diagnosis. Drinking levels of 
mothers of controls who drank were lower than mothers of children with ARND and 
substantially lower than mothers of children with FAS or PFAS, especially during trimesters 
2 and 3. Mothers of children with FAS drank the most: 90% reported drinking an average of 
16.5 drinks per week during the index pregnancy mostly on Fridays and Saturdays, 7.5 
drinks per drinking day, and bingeing three or more drinks per occasion (74%) or five or 
more drinks per occasion (66%). Drinking frequency and quantities were less than FAS 
levels among mothers of children with PFAS, ARND, and controls; however, mothers of 
children with ARND drank twice as frequently during pregnancy than did mothers of 
children with PFAS (0.8 vs 1.6 days per week).
3.5 Correlating alcohol use with outcomes
Partial correlation analysis measured associations between maternal drinking and seven 
child outcomes after adjusting for a confounder, SES (household income and mother’s 
education). Transformations were undertaken for most measures due to positive skewness. 
Logarithmic transformations were applied to number of drinks per drinking day, average 
number of drinks per week, verbal and non-verbal IQ, and digit span performance. Square 
root transformations were applied to behavior and inattention problems, income, and 
education. Although highly unbalanced, transformations could not be applied to “yes/no” 
items: reported drinking and the two measures of binge drinking. A criterion of p < .012 was 
set to control for Type I familywise error rate.
Drank during pregnancy, drinks per drinking day, and drinks per week correlated 
significantly with virtually all cognitive scores using Bonferroni-adjusted values. Verbal and 
nonverbal IQ and Digit Span performance were also significantly lower with drinking during 
pregnancy. Several relationships between drinking during pregnancy and behavior problems 
were positive and statistically significant, including behavior problems and inattention. 
Drinking during pregnancy and inattention correlated with the number of drinks per drinking 
day, drinks per week, and binges of 5 or more drinks. However, none of the above partial 
correlations were particularly strong once adjusted for SES measures, with r ranging from −.
143 to −.250. Thus, each of the latter drinking variables accounts for only about 3% of the 
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variance in the child’s cognitive or behavioral scores. The remaining behavioral measures 
also indicate positive relationships but fail to meet strict statistical criterion.
The binge drinking measure of 3+ drinks per occasion correlated significantly with two of 
the cognitive and behavioral measures in the expected direction. Five or more drinks per 
occasion was significantly related to all cognitive/behavioral measures; all were in the 
expected direction, but were not particularly strong.
Maternal drinking measures correlated most highly with total dysmorphology score after 
adjusting for SES, with drinks per drinking day (r =.302) and drinks per week (r =.313) 
having the highest coefficients. Child’s head circumference was also significantly correlated 
with every drinking measure (r = −.216 to −.306, p<.001).
3.6 Tobacco and other drug use
A significantly higher percentage of FASD mothers reported smoking during the index 
pregnancy (Table 4). A high percentage of women smoked, but average quantity was 
relatively low, 20 to 29 cigarettes per week, and did not differ across groups. Use of other 
drugs was very low and not significantly different among groups in lifetime or pregnancy 
(0.0 to .05% in the FASD groups, and 1.3% for control groups).
3.7 Distal maternal risk– physical, childbearing, and demographic
Mothers of children with FASD were significantly older at the birth of index child, shorter, 
lower in weight, and had lower BMI, smaller OFC, higher parity, and lower educational 
achievement and income. Ninety-four percent (94%) of the mothers of FAS children 
breastfed for a duration of 26.4 months. More children with FASD underwent gestation in 
rural areas.
3.8 Prevalence estimates by three methods and final estimates
Final diagnoses of the children with FASD in the consented sample are presented in Table 6, 
section 1. No cases of ARBD were found. Sixty-nine children were diagnosed with FAS, 91 
with PFAS, and 39 with ARND.
The first estimation technique using two different denominators is summarized in the left 
section of Table 6: number of children enrolled in 1st grade (n=1,172) and total number of 
consented study participants (n=862). The assumption is that oversampling small children 
provides the greatest inclusion of children with FAS or PFAS. The rate of FAS with this 
technique is 58.9 – 79.4 per 1,000, and total FASD is 169.8 – 230.9 per 1,000.
A second rate was calculated from the 83 cases of FASD found within the 347 fully 
examined and tested randomly-selected children (middle section). From this technique the 
rates are: 77.8 FAS cases per 1,000 (95% CI = 49.6 to 105.9) and total FASD of 239.2 per 
1,000 (95% CI = 194.3 to 284.1).
The third rate (Table 6, right section) estimates the total number of cases likely to be found 
in the unconsented children (“b”) and adds these cases to those diagnosed among consented 
children (“a”). The proportions of FASD diagnoses in the random sample (middle section, 
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column 2) were used to estimate the number of cases among unconsented children (column 
3, “b”) which were then added to cases diagnosed in the consented children (a+b =273). The 
rate of FAS is therefore estimated as 79.4 per 1,000 and total FASD as 232.9 per 1,000 or 
23%.
Convergence is substantial among the rates from the three techniques (Figure 5). The final 
range of rates that most accurately characterizes FASD prevalence in this sample is 170 per 
1,000 (total cases diagnosed among examined children over the total school enrollment-
technique 1) and the high estimate of 233 of all enrolled students from technique 3.
4. DISCUSSION
4.1 Summary findings for the community
The physical, cognitive, and behavioral traits of the children with FASD and the controls in 
this general population sample are very similar to those found previously over a 15-year 
period and especially in sample 4 (May et al., 2013a). Child physical growth and 
development and many minor anomalies in this sample most often followed a linear fashion 
by the diagnostic categories of the revised IOM criteria. No cases of isolated ARBD were 
found, which has been a common experience with population-based and clinical studies. 
Major structural anomalies associated with heavy prenatal alcohol exposure are rarely found 
in isolation from cognitive and behavioral problems in most populations; when prenatal 
alcohol use is sufficient to cause major malformations, alcohol exposure has been sufficient 
to also cause other physical anomalies and cognitive/behavioral problems that qualify for 
another FASD diagnosis. This research has again linked specific child traits, especially 
dysmorphology, to detailed maternal reports of prenatal alcohol use. Such links to specific 
quantity, frequency, and gestational timing are rare in other studies due to inaccurate 
reporting of alcohol use. An exception is that prospective longitudinal studies have 
effectively documented the dose-dependent effects of alcohol on development (Alvik et al., 
2013; Burden et al., 2005; Day et al., 2013; Jacobson and Jacobson, 2002; Jacobson et al., 
2013; Streissguth et al., 1994).
Additionally, many distal variables of maternal risk were similar in this study to previous 
studies in the WCP. Less than optimal maternal health (e.g., low BMI from inadequate 
nutrition), SES, and other challenges for child growth and development were associated with 
a higher prevalence of the more severe forms of FASD. In similar studies in the USA, we 
have found more cases of ARND per number of children with FAS and PFAS, most likely 
due to less prevalent and more sporadic binge drinking coupled with more favorable health, 
nutrition, and SES conditions (May et al., 2014b, 2016a).
4.2 Prevalence estimates
The prevalence estimates from the three techniques are convergent. The highest prevalence 
rate that we report corrected for estimated cases in the non-consented children (technique 2). 
The final range of total FASD reported is 170 to 233 per 1,000 or 17 – 23%.
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4.3 Linking findings to prenatal alcohol use
Since all parts of the study were performed blinded by professionals from several 
disciplines, linking of the different domains for final diagnosis is important. Furthermore, 
the traits and diagnoses of the children are linked to reports of maternal prenatal use of 
alcohol in over 87% of the FASD cases, and remaining cases were frequently linked by 
collateral reports from relatives, neighbors, and other propinqutous and knowledgeable 
individuals. Correlation analysis further associates drinking to child traits. More drinking 
during pregnancy, especially binge drinking, yields more minor anomalies and poorer 
performance on cognitive/behavioral measures. The association of drinking and 
neurobehavioral performance, however, was not as strong as correlations with 
dysmorphology. As demonstrated elsewhere (May et al., 2011b, 2013c), dysmorphology 
correlates most highly with drinking even after controlling for multiple confounders. Distal 
maternal risk variables differ across the maternal groups and are associated with additional 
individual variation in child outcomes over and above that caused by differing alcohol use 
patterns alone. Mothers who exhibit more distal risk factors often bear children with poorer 
outcomes and abilities.
4.4 FASD as a cause of microcephaly and public health implications
This sample again indicates that prenatal exposure to alcohol is a major cause of deficient 
brain growth measured by OFC. Furthermore, microcephaly is an important indicator of risk 
for cognitive and behavioral problems as illustrated by the high prevalence of microcephaly 
in the poorly performing children with FAS and ARND. Alcohol as a cause of microcephaly 
has existed in the shadow of other teratogens like mercury, rubella, thalidomide, and now 
zika virus. The prevalence of microcephaly in children with FASD can and should be 
compared with microcephaly rates caused by other teratogens. Alcohol is left out from 
discussions of microcephaly, and more attention is needed to the fact that prolonged and 
heavy prenatal exposure to alcohol is a major cause of poor brain and cerebral development 
which is significantly associated with poor cognitive/behavioral performance.
4.5 Why are more children diagnosed with FAS and PFAS than ARND?
In this sample, there were far more children diagnosed with FAS and PFAS than with 
ARND. This raises some questions regarding how to interpret the lower prevalence of 
ARND in this sample and other studies in ZA communities. There are four major influences 
on the number of PFAS and ARND children diagnosed. First, our methods lead with 
preliminary assessment of poor growth and dysmorphology making it likely that we will 
identify most every child with FAS and PFAS in the population, but less likely that we will 
capture most children with ARND. Second, except for a few children with ARND picked up 
from those who were randomly-selected, the vast majority were diagnosed because our 
clinical team deferred every child with an OFC <10th centile for testing and their mothers for 
a maternal interview. Third, in this predominantly low SES population with undernutrition 
for most vital nutrients (May et al., 2014b, 2016a) and much drinking in the first two 
trimesters (May et al., 2013b), physical traits (dysmorphology) are obviously and most 
severely affected (May et al., 2011, 2013c). Fourth, the cognitive tests and behavioral 
checklists used in ZA epidemiology studies are, by necessity, not extensive or sophisticated 
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enough to detect a broad range of specific and particular deficits (e.g., multiple executive 
functioning traits) that might qualify more children for ARND.
4.6 Why did children with ARND perform worse on neurobehavioral measures than 
children with PFAS?
Mothers of children with PFAS and those with ARND differ in drinking pattern in ways that 
may produce more dysmorphia in children with PFAS; yet these drinking patterns may 
provide a relative advantage for children with PFAS in cognitive and behavioral 
performance. First, while mothers of children with PFAS report more drinks per prenatal 
drinking day overall than those of children with ARND, they report a significantly lower 
average number of drinking days per week during pregnancy overall (0.8 vs. 1.6 days) and in 
1st (2.0 vs. 2.2 days) and 2nd (2.0 vs. 2.3 days) trimesters than mothers of ARND children. 
Second, mothers of children with PFAS are more likely to abstain in the third trimester (77% 
vs 59%) than mothers of children with ARND. Therefore, children with ARND have been 
exposed to prenatal alcohol more frequently than those with PFAS. Third, children with 
PFAS also have significantly shorter PFL than children with ARND, an indicator of 
compromised brain development in the 1st trimester. Fourth, average head circumference of 
PFAS children is significantly larger than children with ARND (50.8 cm vs. 49.5 cm), likely 
due to fewer drinking days and less drinking in the 3rd trimester by the mothers of children 
with PFAS. This is further explained by the procedures in our study; the great majority of 
children with ARND were ascertained because of a referral to testing because of small OFC: 
87.2% of ARND cases had OFC < 10th centile. For children with PFAS, in which a small 
OFC is optional, only 25.3% had OFC < 10th. Fifth, mothers of children with PFAS reported 
more protective distal factors for neurodevelopment (May et al., 2008, 2013) than mothers of 
children with ARND. They have significantly higher income and higher educational 
achievement and are taller, heavier, and lower parity. Therefore, children with PFAS may be 
performing better on the cognitive/behavioral measures as a relative benefit from: lower 
frequency of prenatal exposure, lack of 3rd trimester exposure, a larger head size, and distal 
maternal protective factors. While children with PFAS are more dysmorphic, possibly due to 
more binge-induced alcohol exposure in the first trimester, they performed better than 
children with ARND who were alcohol-exposed more frequently throughout pregnancy.
4.7 Strengths and limitations
The strengths of this study are substantial. 1) It benefited from a high participation rate 
among children (73.5%) and their mothers (over 87.5%), and few cases lost to incomplete 
follow-up. 2) The study utilized a randomly-selected, fully screened, normal comparison/
control group from the same community ensuring relevant and accurate comparisons of 
child groups who were all living in similar community conditions. 3) Complete 
dysmorphology exams were coupled with cognitive/behavioral assessments for all children 
in the final sample. 4) Detailed, direct reports of prenatal alcohol use by quantity, frequency, 
and gestational timing of consumption were linked to child outcomes. 5) Distal maternal risk 
factors were determined from direct, in-person interviews and linked to specific child 
outcomes. 6) Three standard demographic/epidemiologic techniques were used to estimate 
prevalence, and convergence of estimated rates provides substantial support for the final 
estimates.
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Limitations of this study are as follows. 1) Since this community is rather unique in the 
world in racial, ethnic, and cultural traits, extrapolating the exact values and findings directly 
to non-ZA populations might be difficult and perilous for some variables (e.g., precise 
amounts of alcohol that pose risk in another population). But general relationships and 
patterns established are robust and may be identifiable in most populations. 2) Maternal 
interviews were administered 7 years post-partum, and poor recall may have negatively 
affected some maternal risk measures. 3) Without accurate alcohol biomarker samples 
administered to the interviewed mothers, it is impossible to know exactly how precise and 
accurate reporting was. 4) Basing much of the initial study sample on child growth and 
dysmorphology, prevalence of ARND is likely under-estimated. However, an exception to a 
low ARND rate may be found in the isolated random-selection rates (technique #2 in Table 
6) where the rate of ARND is indeed higher than that in other rate estimation techniques. 5) 
Finally, administering a more extensive battery of cognitive/behavioral instruments is 
desirable, but time and monetary resources made this impossible. The battery used was 
somewhat comprehensive and yet economical as is required in a large epidemiologic study.
4.8. Conclusions
FASD prevalence has remained high in this community. A historically-common pattern of 
recreational drinking on weekends, coupled with poverty conditions, combine for high 
prevalence of FASD. The traits of children with FAS, PFAS, and ARND in this population 
are clearly different from one another and from normal controls on multiple child traits and 
multiple risk variables for their mothers. The rate of FAS of 59 to 79 per 1,000 is extremely 
high, as are rates of PFAS and ARND. Total FASD of 17 to 23% is much higher than any of 
the research team initially thought likely in a general population when work commenced in 
this community in 1997. High prevalence again raises the need for prevention and 
intervention.
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Research Highlights
• High rates of fetal alcohol spectrum disorders were again found in this 
community.
• Fetal alcohol syndrome prevalence is 59 – 79 per 1,000 children.
• Total FASD prevalence is 17% – 23%.
• Prenatal alcohol use correlated with poor physical and behavioral 
outcomes.
• Distal maternal risks include: high parity, low BMI, SES, and head 
circumference.
May et al. Page 16
Drug Alcohol Depend. Author manuscript; available in PMC 2017 November 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 1. 
Sampling Methodology for Prevalence of FASD in a Fifth Sample in a South African 
Community
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Figure 2. 
Institute of Medicine Diagnostic Guidelines for Specific Fetal Alcohol Spectrum Disorders 
(FASD) as Clarified by Hoyme et al., 2005
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Figure 3. 
Occipitofrontal (head) Circumference (OFC) by Measurement (cm) and Age-specific 
Percentage and Total Dysmorphology Scores by Diagnostic Category for a Fifth Sample in a 
South African Community
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Figure 4. 
WISC-IV Digit-Span Scaled Scores by Diagnostic Category for a Fifth Sample in a South 
African Community
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Figure 5. 
Final Prevalence Rates (per 1,000) of FASD Diagnostic Groups and Controls in a Fifth 
Sample in a South African Community
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